Patients with ERBB2-positive breast cancer and CNS-only metastasis are at a high risk for CNS-related death but have longer overall survival than those with concomitant extracranial metastases.

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

In patient-derived and animal tumour models, mubritinib suppressed glioblastoma stem cells and tumour growth by targeting ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Objective Elucidating complex ecosystems and molecular features of gallbladder cancer (GBC) and benign gallbladder diseases is pivotal to proactive cancer prevention and optimal therapeutic ...